

Luminex[®]
complexity simplified.

"Keeping Up With COVID - One Company's Story"

Harriss Currie

CFO, Treasurer and Senior VP Finance



LUMINEX CORPORATION: FULLY EMBEDDED IN GLOBAL BIOMEDICAL SCIENCE AND HEALTHCARE ENTERPRISES

Actionable solutions across the biomedical spectrum

Luminex is a biotech company providing molecular, proteomic, and cellular analysis tools and tests to life science and diagnostics markets exceeding \$12B per year.

VISION

We seek to enable labs around the world to quickly advance science and deliver beneficial, cost-effective healthcare solutions

LUMINEX CORPORATION: WHO WE ARE

ATTRACTIVE MARKETS

- Serving a growing \$12B+ global life science marketplace
- Flexibility in reaching customers through direct sales, strategic partnerships, and other channels

DIVERSIFIED SOLUTIONS


- Differentiated platforms and assays, supported by 850+ patents, to address the needs of our clinical, biopharmaceutical, and research customers
- Enabling molecular, proteomic and cellular analysis

FINANCIAL STRENGTH & GLOBAL REACH


- Healthy profitability, increasing quarterly dividend, consistent cash flow and strong balance sheet
- ~25,000 instruments worldwide driving 75% annuity revenue

OUR STORY

WE HELP LABS OBTAIN ANSWERS TO CHALLENGING MEDICAL QUESTIONS BY PROVIDING SOLUTIONS FOR DIAGNOSTIC AND RESEARCH PURPOSES.



DEVELOPING SOLUTIONS DURING THE COVID-19 PANDEMIC




PCR-BASED TESTS

- Two Luminex PCR-based COVID-19 tests have already received EUA clearance
- Run on ARIES and NxTAG Systems
- Expecting EUA clearance on NxTAG RPP+SARS-CoV-2 Assay any day
- ARIES A/B & RSV + SARS-CoV-2 Assay EUA submission is ready to go to FDA
- Planning for EUA submission to FDA for VERIGENE II RSP *Flex* Assay later this quarter




ANTIBODY-BASED TESTS

- xMAP Multi-Antigen IgG assay has received EUA clearance
- Developing additional antibody tests to help identify individuals who may have some level of immunity to the virus
- Anticipate submitting EUA submission to FDA for xMAP-based Neutralization Assay in Q2 '21



MULTIPLE COVID-19 SOLUTIONS FOR THE LONG RUN



Molecular Testing

ARIES®

- Targeted, sample-to-answer diagnostic testing

VERIGENE®

- Syndromic, sample-to-answer diagnostics and surveillance

Serology Testing

MAGPIX®

- Syndromic, high-throughput, cost-effective diagnostic testing
- SARS-CoV-2 serology testing for immunity monitoring, vaccine development

Vaccines/
Therapeutics/
Cell Research

**LUMINEX® 200™
FLEXMAP 3D®**

- High-throughput, multiplex serology, cytokine & proteomic research

**xMAP®
INTELLIFLEX**


- High-throughput, multiplex serology research
- Vaccine, therapeutic, cytokine & proteomic research



SHORT/MID-TERM: DIAGNOSTICS AND SEROLOGY HELP FLATTEN THE CURVE

LONG TERM: RESEARCH, THERAPEUTICS AND VACCINES HELP LOWER THE CURVE

SARS-CoV-2 MDx PROJECTS



Launched
Submitted

NxTAG® CoV Extended Panel
NxTAG® RPP+SARS-CoV-2 (CE-IVD)

ARIES® SARS-CoV-2 Assay
(EUA, CE-IVD and LDT)

NxTAG® RPP + SARS-CoV-2 Panel

VERIGENE® SARS-CoV-2 Assay



NxTAG® RPP v2 (IVD)

- Includes updated Flu and other targets*
- Submitting for EUA in March



ARIES® Flu A/B & RSV + SARS-CoV-2 (EUA)

- Uses Taqman for improved MFG
- Submitting for EUA 2/25

ARIES® Flu + SARS-CoV-2 Fast

- Tech Feasibility underway for ~60-75 min version



VERIGENE® SARS-CoV-2 (EUA)

- Pooling claim (5 samples)
- LoD of 100 copies/ml
- Submitted in Jan '21
- Reprioritized by FDA



VERIGENE® II RSP Flex + SARS-CoV-2 (EUA)

- Built on RP Flex panel
- 3 gene CoV target add to PCR tube 4
- Finalizing submission package

VERIGENE® II RSP Flex + SARS-CoV-2 (RUO)


- Launch planned for Q2 '21

VERIGENE® II RSP Flex + SARS-CoV-2 (CE-IVD)

- Launch planned for Q3 '21

xMAP® SARS-CoV-2 MULTI-ANTIGEN IgG ASSAY

Example of a bead in the assay



Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results:

- S1 subunit of the spike protein
- Receptor Binding Domain (RBD) of the spike protein
- Nucleocapsid protein

EXPANDED MANUFACTURING TO MEET INCREASED DEMAND

Austin/ARIES®

- **600K** test capacity. Beginning of 2020
- **1.6M** test capacity. Summer 2020
- **3.2M** test capacity (investment of ~\$5M). Ready now!
- **4.5M** test capacity (investment of \$1M). Mid-2021
- **6M+** test capacity (investment of ~\$5M). Beginning of 2022
- **50K** sq ft facility expansion. Mid-2021

Toronto/NxTAG®

- **1M** test capacity. Beginning of 2020
- **9M** test capacity (investment of \$500K). Summer 2020

Chicago/VERIGENE®

- **~25%** increase in footprint (\$8M facility purchase). Q1 2021
- **600K** test capacity (VERIGENE II fully automated lines)
- **1.2M** test capacity (VERIGENE I)
- **\$3.4M** total investment (already paid)

Madison/Reagents

- **10%+** increase in building footprint (investment of \$2.5M)
- Supports both ARIES® and VERIGENE II

Luminex[®]
complexity simplified.

Questions?

